NSQIP与CESQIP在数据质量及甲状腺切除术结局预测能力的比较
本研究比较NSQIP与CESQIP在单中心和国家层面数据完整性与预测甲状腺切除术结局的能力。单中心66例一致,国家层面NSQIP纳入24942例、CESQIP纳入17666例。CESQIP对甲状腺特异并发症和再手术预测更优,但数据缺失率更高(27.22% vs 3.44%)。
要点
- CESQIP对甲状腺特异并发症和再手术的预测能力优于NSQIP。
- NSQIP对再入院的预测能力优于CESQIP。
- CESQIP数据缺失率显著高于NSQIP(27.22% vs 3.44%)。
核心结论
- CESQIP对甲状腺切除术特异并发症和再手术的预测更准确,凸显其收集细粒度疾病特异变量的价值。
- NSQIP数据采集更严谨,但CESQIP对甲状腺特异结局的预测更好。
研究设计与样本
- 单中心分析纳入2013-2020年同时录入CESQIP和NSQIP的66例甲状腺切除术病例,使用McNemar检验评估数据一致性。
- 国家层面分析使用2016-2019年NSQIP的24942例和CESQIP的17666例甲状腺切除术病例,比较4种结局的预测能力(AUC)。
主要发现
- 国家层面NSQIP的30天甲状腺特异并发症、全身并发症、再入院和再手术率分别为13.25%、2.13%、1.74%和1.39%;CESQIP分别为7.27%、1.95%、1.64%和0.81%。
- NSQIP预测再入院的AUC为0.721(95%CI 0.703-0.737),CESQIP为0.613(95%CI 0.581-0.649)。
- CESQIP预测甲状腺特异并发症的AUC为0.724(95%CI 0.708-0.737),NSQIP为0.677(95%CI 0.667-0.687)。
- CESQIP预测再手术的AUC为0.735(95%CI 0.692-0.775),NSQIP为0.643(95%CI 0.611-0.673)。
临床怎么用
- 关注甲状腺特异并发症和再手术时,CESQIP的预测模型可能更适用。
- 使用CESQIP数据时需注意其较高的缺失率可能影响结果解读。
- NSQIP在再入院预测和数据完整性方面更具优势,可根据结局选择数据库。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Collaborative Endocrine Surgery Quality Improvement Program tracks thyroidectomy outcomes with self-reported data, whereas the National Surgical Quality Improvement Program uses professional abstractors. We compare completeness and predictive ability of these databases at a single-center and national level. METHOD: Data consistency in the Collaborative Endocrine Surgery Quality Improvement Program and the National Surgical Quality Improvement Program at a single institution (2013-2020) was evaluated using McNemar's test. At the national level, data from the Collaborative Endocrine Surgery Quality Improvement Program and the National Surgical Quality Improvement Program (2016-2019) were used to compare predictive capability for 4 outcomes within each data source: thyroidectomy-specific complication, systemic complication, readmission, and reoperation, as measured by area under curve. RESULTS: In the single-center analysis, 66 cases were recorded in both the Collaborative Endocrine Surgery Quality Improvement Program and the National Surgical Quality Improvement Program. The reoperation variable had the most discrepancies (2 vs 0 in the National Surgical Quality Improvement Program versus the Collaborative Endocrine Surgery Quality Improvement Program, respectively; χ2 = 2.00, P = .16). At the national level, there were 24,942 cases in the National Surgical Quality Improvement Program and 17,666 cases in the Collaborative Endocrine Surgery Quality Improvement Program. In the National Surgical Quality Improvement Program, 30-day thyroidectomy-specific complication, systemic complication, readmission, and reoperation were 13.25%, 2.13%, 1.74%, and 1.39%, respectively, and in the Collaborative Endocrine Surgery Quality Improvement Program 7.27%, 1.95%, 1.64%, and 0.81%. The area under curve of the National Surgical Quality Improvement Program was higher for predicting readmission (0.721 [95% confidence interval 0.703-0.737] vs 0.613 [0.581-0.649]); the area under curve of the Collaborative Endocrine Surgery Quality Improvement Program was higher for thyroidectomy-specific complication (0.724 [0.708-0.737] vs 0.677 [0.667-0.687]) and reoperation (0.735 [0.692-0.775] vs 0.643 [0.611-0.673]). Overall, 3.44% vs 27.22% of values were missing for the National Surgical Quality Improvement Program and the Collaborative Endocrine Surgery Quality Improvement Program, respectively. CONCLUSION: The Collaborative Endocrine Surgery Quality Improvement Program was more accurate in predicting thyroidectomy-specific complication and reoperation, underscoring its role in collecting granular, disease-specific variables. However, a higher proportion of data are missing. The National Surgical Quality Improvement Program infrastructure leads to more rigorous data capture, but the Collaborative Endocrine Surgery Quality Improvement Program is better at predicting thyroid-specific outcomes.
引用
- Hsiao V, Kazaure HS, Drake FT, et al. A comparison of NSQIP and CESQIP in data quality and ability to predict thyroidectomy outcomes. Surgery. 2022. PMID: 36402607. doi:10.1016/j.surg.2022.05.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。